Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils
In the past 25 years, a considerable number of therapeutic monoclonal antibodies (mAb) against a variety of tumor-associated antigens (TAA) have become available for the targeted treatment of hematologic and solid cancers. Such antibodies opsonize cancer cells and can trigger cytotoxic responses med...
Main Authors: | Leonie M. Behrens, Timo K. van den Berg, Marjolein van Egmond |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/14/3366 |
Similar Items
-
Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer
by: ZHA Li, et al.
Published: (2018-08-01) -
Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
by: Erik Voets, et al.
Published: (2019-12-01) -
Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
by: Jinyang Hu, et al.
Published: (2020-11-01) -
A New Serum Macrophage Checkpoint Biomarker for Innate Immunotherapy: Soluble Signal-Regulatory Protein Alpha (sSIRPα)
by: Yoanna V. Vladimirova, et al.
Published: (2022-07-01) -
Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
by: Haiqin Liao, et al.
Published: (2022-04-01)